Literature DB >> 17853025

A rational combination of intravesical and systemic agents for the treatment of interstitial cystitis.

Rajesh Taneja1, Kailash K Jawade.   

Abstract

OBJECTIVE: Interstitial cystitis is a condition with a poorly understood etiology and, consequently, various treatment options have been described in the literature, with a less than optimal outcome. The aim of this study was to examine the role of a combination of intravesical hydrocortisone and heparin, together with oral bladder sedatives and systemic triamcinolone, for the treatment of interstitial cystitis.
MATERIAL AND METHODS: A total of 26 patients who were diagnosed as having interstitial cystitis were treated with weekly intravesical hydrocortisone (200 mg) and heparin (25,000 IU) in physiological saline for 6 weeks. In addition, they were given oral bladder sedatives such as oxybutynin or tolterodine. Ulcerative, refractory and recurrent cases were treated with intramuscular triamcinolone (40 mg) weekly for 6 weeks.
RESULTS: All patients experienced an improvement in symptoms within 48 h of their first intravesical instillation. While 19 patients (73%) experienced almost complete pain relief, five of the remaining seven patients improved with intramuscular triamcinolone. Frequency reduced from a mean of 23.2 to 10.9 voids per day and was acceptable in 21 patients (80%). Six patients (23%) had a relapse of symptoms in the form of pain and were treated satisfactorily by means of intramuscular triamcinolone. The mean duration of follow-up was 18.3 months.
CONCLUSION: A combination of intravesical hydrocortisone and heparin, along with oral bladder sedatives and systemic steroids, has been used with encouraging results in a small group of patients with interstitial cystitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17853025     DOI: 10.1080/00365590701435918

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  4 in total

1.  Intravesical lignocaine in the diagnosis of bladder pain syndrome.

Authors:  Rajesh Taneja
Journal:  Int Urogynecol J       Date:  2010-03       Impact factor: 2.894

2.  Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain.

Authors:  W F Goins; J R Goss; M B Chancellor; W C de Groat; J C Glorioso; N Yoshimura
Journal:  Gene Ther       Date:  2009-02-26       Impact factor: 5.250

3.  Evidence for the Role of Mast Cells in Cystitis-Associated Lower Urinary Tract Dysfunction: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Animal Model Study.

Authors:  Xu Wang; Wujiang Liu; Michael O'Donnell; Susan Lutgendorf; Catherine Bradley; Andrew Schrepf; Liwei Liu; Karl Kreder; Yi Luo
Journal:  PLoS One       Date:  2016-12-21       Impact factor: 3.240

4.  Sub-noxious Intravesical Lipopolysaccharide Triggers Bladder Inflammation and Symptom Onset in A Transgenic Autoimmune Cystitis Model: A MAPP Network Animal Study.

Authors:  Paul Kogan; Suming Xu; Yaoqin Wang; Michael A O'Donnell; Susan K Lutgendorf; Catherine S Bradley; Andrew Schrepf; Karl J Kreder; Yi Luo
Journal:  Sci Rep       Date:  2018-04-26       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.